SciClone Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year 2016
For the six months, the company reported total net revenue of USD 75,490,000 compared to USD 71,514,000 a year ago. Income from operations was USD 15,377,000 compared to USD 4,626,000 a year ago. Income before provision for income tax was USD 15,778,000 compared to USD 4,964,000 a year ago. Net income USD 14,202,000 or USD 0.27 per diluted share compared to USD 4,940,000 or USD 0.09 per diluted share a year ago. Non-GAAP net income USD 20,392,000 or USD 0.39 per diluted share compared to USD 23,316,000 or USD 0.44 per diluted share a year ago.
For the year 2016, the company expects revenue to be in the range of USD 158 million to USD 163 million and expects that non-GAAP earnings per share on a fully diluted basis to be in the range of USD 0.70 to USD 0.74 for the year.